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http://dx.doi.org/10.1016/j.kjms.201Abstract Preoperative elevation of serum C-reactive protein (CRP) is reportedly associated
with poor prognosis in several types of cancer. This study investigated the role of serum CRP
as a prognostic factor in early-stage esophageal squamous cell carcinoma (ESCC). The preop-
erative serum CRP levels were measured in 156 newly diagnosed pT1e2N0M0 patients using an
enzyme-linked immunosorbent assay. Correlations between serum CRP levels and other clinical
parameters were analyzed. Multivariate analyses were performed to find prognostic markers
using Cox’s proportional hazards model. CRP concentrations were within the normal range in
117 (75%) individuals, but were elevated in 39 (25%) patients. Serum CRP levels were signifi-
cantly correlated with the tumor length (p Z 0.032), depth (T classification, p Z 0.0157),
or histologic grade (p Z 0.034). The overall 5-year survival rates were 76.3% and 50.2% in
the low- and high-CRP groups, respectively (pZ 0.005). By multivariate analyses, the elevated
serum CRP level was found to be an independent prognostic factor for poor survival (hazard
ratio Z 2.131; p Z 0.007), regardless of tumor classification or other prognostic factors. In
conclusion, preoperative, high serum CRP is an independent determinant of poor prognosis
in early-stage ESCC.
Copyright ª 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.of Chemotherapy, Zhejiang Cancer Hospital, 38 Guangji Road, Hangzhou 310022, China.
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C-reactive protein (CRP), generally produced by hepato-
cytes, is an acute-phase protein, whose levels increase in
various inflammatory conditions [1]. Furthermore, CRP has
been reported as a predictor of survival in different ma-
lignancies, including pancreatic [2], ovarian [3], pulmonary
[4], and colorectal [5] cancers. However, its role in early-
stage esophageal squamous cell carcinoma (ESCC) has not
been characterized well. In this study, we aimed to inves-
tigate the relationship between the preoperative elevation
of serum CRP level and clinical features of early-stage ESCC
and to establish its possible role as a prognostic marker for
ESCC patients.
Patients and methods
The study participants comprised 156 patients who un-
derwent curative resection of ESCC in our department
between January 2004 and July 2010. Patients with in-
flammatory conditions, including infections or collagen
diseases, and those with primary cancers in other organs,
all of which possibly influence the serum CRP levels, were
excluded. The patients who did not die of disease pro-
gression were excluded from our study. No study patient
had received induction chemotherapy or radiotherapy.
The tumor-node-metastasis (TNM)-stage classification was
assessed according to the 2009 American Joint Committee
on Cancer (AJCC) staging system [6]. Preoperative evalu-
ations and staging workups included recording patients’
medical histories, physical examinations, complete blood
cell counts, serum biochemistry tests, thoracic computed
tomography (CT), upper abdominal ultrasounds, magnetic
resonance brain imaging, entire body bone scans, and
positron emission tomography (PET) scans (partly with
PET/CT). All patients were confirmed by pathological T1
or T2 signals without lymph-node metastases after
surgery.
Measurement of serum CRP
Serum was collected 1 day prior to the operation to mea-
sure the CRP level, which was determined once for each
patient. Serum CRP was measured using a CRP ELISA
(enzyme-linked immunosorbent assay) kit (Westtang Cor-
poration, Shanghai, China). The normal serum CRP range is
0e5 mg/L. Hence, a serum CRP concentration of >5 mg/L
was considered positive.
Patient follow-up
Surviving patients were followed-up every 3e6 months for
the first 5 years, and then once annually. Each patient’s
history, physical examination, and thoracic CT scans were
recorded at each follow-up session. Survival time was
recorded from the 1st day of operation to the date of
death or the last follow-up visit. July 1, 2011 was the last
censoring date for survival. The median survival time from
surgery to the last censoring date was 56 months (range,
12e84 months).Statistical analysis
The Chi-square test was used to compare the data. Survival
curves were generated using the KaplaneMeier method
from the start of confirmed pathology to the date of death
or last follow-up. Multivariate analysis was performed using
the Cox regression model. Statistical analysis was per-
formed with the SPSS version 16 software (SPSS Inc., Chi-
cago, IL, USA). Confidence intervals were calculated at the
95% level (95% CI). Follow-up extended through January 1,
2012.Results
A total of 156 patients, including 134 men and 22 women
(median age, 59 years; range, 31e78 years) were enrolled
in our study. Patients’ tumors were histologically
confirmed to be ESCC. Tumors were located in the upper
third in 10 (6.4%) patients, in the middle third in 82 (52.6%)
patients, and in the lower third of the esophagus in 64
(41%) patients. In total, 112 individuals (71.8%) underwent
Ivor-Lewis esophageal resection, and 44 individuals un-
derwent tri-incisional esophageal resection or other sur-
gical procedures. The average number of resected lymph
nodes was 24.9 (range, 12e72). Thirty-nine and 116 pa-
tients underwent three- and two-field lymph-node dis-
sections, respectively. Serum CRP levels were higher than
5 mg/L in 39 patients and lower than 5 mg/L in 117 pa-
tients. Median CRP levels were 3.9 (95% CI, 3.6e4.1) and
21.2 (95% CI, 13.1e41.2) in the low- and high-CRP groups,
respectively. Table 1 shows the relationship between
serum elevation of CRP and clinicopathological charac-
teristics of study patients. Significant differences were
found in the tumor length (p Z 0.032), depth of tumor
invasion (p Z 0.0157), and histological tumor grading
(p Z 0.034).Factors affecting overall survival by univariate and
multivariate analyses
Univariate analyses were performed using the KaplaneMe-
ier method to assess the predictive capacity of each tested
variable (Table 2). Pathologic T classification (p Z 0.029),
tumor length (pZ 0.043), and CRP levels (pZ 0.005) were
predictive of survival.
As Fig. 1A demonstrates, there was a significant differ-
ence in survival time between the low- and high-CRP group
(the 5-year survival rates were 76.3% and 50.2% in the low-
and high-CRP groups, respectively; p Z 0.005). The 5-year
disease-free survival rates were 60.4% and 40.5% in the low-
and high-CRP groups, respectively (p Z 0.036; Fig. 1B).
There was a significant difference in survival time between
the low- and high-CRP groups with T1 and T2 classification
patients (Fig. 2A and B).
A multivariate Cox’s regression model was constructed
considering age, sex, T status, histologic grade, tumor
location, tumor length (3 cm vs. 3 cm), serum albumin
level (SAL), and CRP levels as variables. T status and
CRP level qualified as independent prognostic factors
(Table 3).
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The data of postoperative CRP were collected from 67 pa-
tients within 6 months after surgery. The difference in
survival rates between the groups with high and low CRP
levels was statistically significant. The overall 5-year sur-
vival rates were 90.6% and 63.6% for the low- and high-CRP
groups, respectively (p Z 0.043; Fig. 3). Based on the
preoperative SALs in all 156 patients, the overall 5-year
survival rates were found to be 70.1% and 52.9% in
normal- and low-SAL groups, respectively (p Z 0.057).Table 2 Results of univariate analysis of the prognosis of
156 patients with esophageal squamous cell carcinoma.






Male 134 80.4 68.2 0.225Discussion
To the best of our knowledge, this is the first study evalu-
ating the clinical significance of serum CRP levels in pre-
dicting survival in early-stage ESCC patients. Multivariate
analyses showed preoperative serum CRP along with path-
ologic T status to be significant, independent prognostic
markers for ESCC.
Previous studies have reported elevation of preoperative
serum CRP levels as a significant prognostic parameter in
patients with some carcinomas [2e10]. Mechanisms un-
derlying CRP elevation are well known. Production of CRP
by liver is strongly induced by cytokines including
interleukin-1, interleukin-6, and tumor-necrosis factor
[11e13]. Interleukin-6 is highly expressed by various tumor
cells. For example, studies using esophageal cancer cellTable 1 Relationship between serum CRP elevation and
the clinicopathological features of patients with early-stage







Male 100 34 0.513
Female 17 5
Age, y
65 25 8 0.554
<65 92 31
Tumor
1 59 11 0.0157
2 58 28
Tumor length, cm






Poorly differentiated 18 12
Tumor location
Upper third 5 5 0.267
Middle third 64 18
Lower third 48 16
Operation procedure
Ivor-Lewis 80 32 0.357
Other 27 7
CRP Z C-reactive protein.lines or esophageal surgical specimens have shown that
some types of esophageal carcinomas produce interleukin-6
[14]. Similar to other proteinaceous markers of acute
inflammation, CRP has several biological roles including
opsonization, chemotaxis, platelet activation, and com-
plement activation by the classical pathway [15]. Recent
studies suggest that CRP functions as a primitive immuno-
globulin by binding to the Fc fragment of immunoglobulins
or to several pathogenic microorganisms [16]. This role of
CRP underlying antitumor immunity apparently correlates
with poor prognosis in carcinomas.
Previously, an elevated serum CRP level was associated
with reduced progression-free patient survival or overall
survival independent of other clinically established prog-
nosticators [17,18]. CRP is reported to be associated with a
negative chemotherapy and radiotherapy response factor.
However, the role of CRP in early-stage ESCC has not been
examined until now. In this study, we found high serum CRP
level as a determinant of poor prognosis in early-stage
ESCC; the 5-year survival rate was lower in patients withFemale 22 89.6 75.8
Age, y
65 33 75.2 73.3 0.832
<65 122 84 65.9
Tumor
1 70 87.6 75.3 0.029
2 86 71.8 60.1
Tumor length, cm
>3 69 71.3 61.6 0.043




126 86.4 76.3 0.069
Poorly differentiated 30 76.3 66.9
Tumor location
Upper third 10 84.3 52.6 0.421
Middle third 82 85.2 76.3
Lower third 64 80.1 69.1
Operation procedure
Ivor-Lewis 122 82.1 72.1 0.681
Tri-incisional 32 80.5 63.5
Other 12 85.3 56.7
Adjuvant therapy
Yes 16 87.7 74.2 0.232
No 140 82.6 66.6
CRP level
5 39 70.1 50.2 0.005
<5 117 89.6 76.3
Serum albumin level
35 131 81.6 70.1 0.057
<35 25 69.8 52.9
CRP Z C-reactive protein.
Figure 2. (A) Overall survival in T1 classification patients
with low versus high preoperative CRP levels (p Z 0.047). (B)
Overall survival in T2 classification patients with low versus
high preoperative CRP levels (p Z 0.003). CRP Z C-reactive
protein.
Figure. 1. (A) Overall survival in patients with low versus
high preoperative CRP levels (p Z 0.005). (B) Disease-free
survival in patients with low versus high preoperative CRP
levels (p Z 0.036). CRP Z C-reactive protein.
Table 3 Factors associated with the prognosis of patients
with esophageal squamous cell carcinoma.
Variables HR 95% CI p
Sex 0.862 0.392e1.895 0.711
Age 0.712 0.389e1.571 0.576
Tumor classification 1.921 1.331e2.917 0.041
Tumor length 0.521 0.417e1.251 0.194
Histologic grade 1.175 0.694e1.994 0.558
Tumor location 1.351 0.573e2.156 0.617
CRP level 2.131 1.213e4.451 0.007
SAL 1.535 0.989e2.135 0.097
CI Z confidence interval; CRP Z C-reactive protein;
HR Z hazard ratio; SAL Z serum albumin level.
C-reactive protein in esophageal carcinomas 665higher CRP levels than in patients with lower CRP levels
(50.2% vs. 76.3%; p Z 0.005).
According to the guidelines of the National Compre-
hensive Cancer Network, systemic chemotherapy is not
recommended in early-stage ESCC. The PT1e2 status
without any lymph-node metastases was a desirable
outcome after complete tumor resection. However, the 5-
year survival time was not favorable. The high-risk factor in
such cases is not well studied in the clinic. Our results
suggest that CRP level may be a useful indicator for defining
a subset of early-stage ESCC patients with unfavorable
prognoses and, thus, requiring intensive treatment. Pa-
tients with high preoperative CRP in the early-stage of the
disease may require intensive systemic chemotherapy
compared to those with low CRP levels.Measurement and quantification of serum CRP levels are
relatively inexpensive and easy in clinical practice. Preop-
erative serum CRP levels can be determined easily in pa-
tients with esophageal cancers. Accordingly, serum CRP, as
Figure 3. Overall survival in patients with low versus high
postoperative CRP levels (p Z 0.043). CRP Z C-reactive
protein.
666 Z.-B. Song et al.a significant prognosticator, can be used with other con-
ventional staging methods to predict survival in patients
with early-stage ESCC.
In conclusion, we suggest that preoperative serum CRP
can be used as a prognostic factor in early-stage ESCC
patients. High CRP levels indicate poor prognoses by
reducing the overall survival times of patients; moreover,
they are likely to complement the prognostic role of TNM
staging. This study had inherent limitations because of its
retrospective nature; hence, the association between
CRP level and survival outcome should be investigated
further.
References
[1] Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related
inflammation. Nature 2008;454:436e44.
[2] Mahmoud FA, Rivera NI. The role of C-reactive protein as a
prognostic indicator in advanced cancer. Curr Oncol Rep 2002;
4:250e5.
[3] Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Marth C,
et al. Serum C-reactive protein as independent prognostic
variable in patients with ovarian cancer. Clin Cancer Res 2008;
14:710e4.[4] Hara M, Matsuzaki Y, Shimuzu T, Tomita M, Ayabe T,
Enomoto Y, et al. Preoperative serum C-reactive protein level
in non-small cell lung cancer. Anticancer Res 2007;27:3001e4.
[5] Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of
preoperative elevation of serum C-reactive protein as an indica-
tor for prognosis in colorectal cancer. Am J Surg 1998;176:335e8.
[6] Edge SB, Compton CC. The American Joint Committee on
Cancer: the 7th Edition of the AJCC cancer staging manual and
the future of TNM. Ann Surg Oncol 2010;17:1471e4.
[7] Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T. Significant host-
and tumor-related factors for predicting prognosis in patients
with esophageal carcinoma. Ann Surg 2003;238:197e202.
[8] Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ,
Stuart RC. An elevated C-reactive protein concentration, prior
to surgery, predicts poor cancer-specific survival in patients
undergoing resection for gastro-oesophageal cancer. Br J
Cancer 2006;94:1568e71.
[9] Kodama J, Miyagi Y, Seki N, Tokumo K, Yoshinouchi M,
Kobashi Y, et al. Serum C-reactive protein as a prognostic
factor in patients with epithelial ovarian cancer. Eur J Obstet
Gynecol Reprod Biol 1999;82:107e10.
[10] Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ.
Evaluation of cumulative prognostic scores based on the sys-
temic inflammatory response in patients with inoperable non-
small-cell lung cancer. Br J Cancer 2003;89:1028e30.
[11] Liao WC, Lin JT, Wu CY, Huang SP, Lin MT, Wu AS, et al. Serum
interleukin-6 level but not genotype predicts survival after
resection in stages II and III gastric carcinoma. Clin Cancer Res
2008;14:428e34.
[12] Ashizawa T, Okada R, Suzuki Y, Takagi M, Yamazaki T, Sumi T,
et al. Clinical significance of interleukin-6 (IL-6) in the spread
of gastric cancer: role of IL-6 as a prognostic factor. Gastric
Cancer 2005;8:124e31.
[13] Forones NM, Mandowsky SV, Lourenc¸o LG. Serum levels of
interleukin-2 and tumor necrosis factor-alpha correlate to
tumor progression in gastric cancer. Hepatogastroenterology
2001;48:1199e201.
[14] Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T,
Iizuka N, et al. Relationship between serum levels of inter-
leukin 6, various disease parameters and malnutrition in pa-
tients with esophageal squamous cell carcinoma. Cancer Res
1996;56:2776e80.
[15] Szalai AJ. The antimicrobial activity of C-reactive protein.
Microbes Infect 2002;4:201e5.
[16] Marnell LL, Mold C, Volzer MA, Burlingame RW, Du Clos TW. C-
reactive protein binds to Fc gamma RI in transfected COS
cells. J Immunol 1995;155:2185e93.
[17] Nozoe T, Saeki H, Sugimachi K. Significance of preoperative
elevation of serum C-reactive protein as an indicator of prog-
nosis in esophageal carcinoma. Am J Surg 2001;182:197e201.
[18] Hong SJ, Kang YA, Cho BC, Kim DJ. Elevated serum C-reactive
protein as a prognostic marker in small cell lung cancer.
Yonsei Med J 2012;53:111e7.
